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ABSTRACT
Objective: Establishing a research agenda on standardizing pain measurement in clinical trials in 
rheumatic and musculoskeletal diseases (RMDs).
Methods: Discussion during a meeting at OMERACT 2018, prepared by a systematic review of 
existing core outcome sets and a patient online survey.
Results: Several key questions were debated: is pain a symptom or a disease? are pain core 
(sub)domains consistent across RMDs? how to account for pain mechanistic descriptors (e.g. central 
sensitization) in pain measurement?
Conclusion: Characterizing and assessing the spectrum of pain experience across RMDs in a 
standardized fashion is the future objective of the OMERACT pain working group.
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MANUSCRIPT
Introduction
Pain is a prevailing and common symptom across rheumatic and musculoskeletal diseases (RMDs) 
(1). Clinically, acute and chronic pain are distinct, are managed differently and have differences in 
outcomes. The majority of people who experience acute pain tend to improve spontaneously or 
under treatment (2), but some individuals progress to a chronic pain that can cause considerable 
physical, emotional, and socioeconomic burdens (3). To identify preventive or effectively tailored 
interventions, standardized pain assessment in clinical trials is essential to making precise estimates 
on the effectiveness of interventions. However, heterogeneity in outcome assessment has been 
identified for clinical trials in patients within and between different pain conditions (4).
OMERACT 2.0 Filter (5, 6) provides guidance for harmonizing outcome assessment by developing 
core outcome sets (COS), consisting of domains and measurement instruments. Defining the scope 
of such a COS is the initial step, identifying the domains that constitute the health condition of 
interest. For pain conditions, several COS recommendations exist, regarding chronic pain in general 
(7, 8), fibromyalgia (9), low back pain (LBP) (10), or for specific treatments (11). To establish a 
research agenda for harmonizing pain assessment in clinical trials in RMDs, information is needed 
regarding: 
1) the importance of chronic pain in patients with RMDs;
2) to what extent patients with chronic pain and RMDs feel different from patients with chronic 
pain of other origin;
3) whether the pain experience is different across RMDs;
4) the existing pain recommendations in COS for RMDs;
5) to what extent pain measurement differs across RMDs;
6) the relative contribution of different pain mechanisms (e.g. central sensitization, 
neuropathic pain) to the patients experience of pain.
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Methods, Results and Meeting Report
Establishing a research agenda was planned for the OMERACT Meeting in Terrigal, Australia, May 
2018. In preparation, the OMERACT pain working group had multiple teleconferences, conducted an 
online survey in patients with RMDs and a systematic review on existing pain recommendations in 
COS for RMDs.
Introduction of the OMERACT 2018 SIG
PJM introduced the precursor working group that developed a COS for FM (9) and proposed a 
composite measure of disease activity to assess the COS (12). This group described the 
multidimensional nature of this chronic pain disorder by itemizing in the COS the following items: 
pain, fatigue, sleep disturbance, patient global, multidimensional function, and quality of life. This 
COS was noted to be closely correlated to the IMMPACT COS for evaluation of chronic pain 
conditions in clinical trials (7, 8, 13).
Following this previous work, a working group has met as a Special Interest Group (SIG) at 
subsequent OMERACT meetings to address the possibility of developing a COS for chronic pain 
across all RMDs. Nevertheless, several inherent problems exist in this standardization process. First, 
pain may be acute and episodic in some RMDs and in others, chronic. In the latter situation, pain 
may become a disease unto itself, including chronic alteration of signaling pathways in the central 
nervous system rather than an episodic symptom of peripheral pathophysiology of a RMD. It has 
been demonstrated that chronic central pain can influence RMD outcomes (14). Characterizing and 
assessing the spectrum of pain experience across RMDs in a standardized fashion was highlighted as 
the objective of this working group, comprised of academic pain researchers and patient research 
partners.
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Importance and experience of chronic pain in RMDs
An online survey (one round between April and May 2018) was held to explore nature and relevance 
of chronic pain in patients with RMDs. The questionnaire was developed by one SIG members (UK) 
and revised by others (BH, MG, MdW, MC, EC, LSS, PJM, AC) with Survey monkey, and data were 
analyzed with frequencies of responses and qualitatively. The majority (84%) of patients reported 
experiencing a RMD AND chronic pain, 86% expressed that chronic pain is relevant for patients with 
various RMDs (Table 1). The majority of the patients (47%) reported that chronic pain is a common, 
inseparable aspect of RMDs.
In a previous survey (13), individuals experiencing chronic pain (n>800) identified 19 (sub)domains to 
be related to and impacted by chronic pain. Similar results were provided by patients with RMDs 
(Table 2, Figure 1). The most important domains (i.e. staying asleep, enjoyment of life, , and fatigue, 
mean N5E34 rating between 0 not important at all, 10 of highest importance) also scored among 
the highest in the previous survey. The most substantial distinction between respondents with RMDs 
and chronic pain was found for weakness and difficulties concentrating (Table 2); such 
difference may be explained by the fact that only a minority of patients presented with a RMD in the 
previous survey (i.e. 5% rheumatoid arthritis, 19% osteoarthritis) (13). Patients also felt that a 
specific treatment of chronic pain in RMDs would be necessary (Median = 7/10). The majority of 
patients (72%) expected treatment of chronic pain to have different aims than other treatments for 
RMDs.
Core Outcome Sets for RMDs
Our aim was to identify any COS for research or practice targeting any RMD. An ad-hoc multifaceted 
search strategy to retrieve COS in MEDLINE and SCOPUS [developed by the Core Outcome Measures 
in Effectiveness Trials (COMET) initiative (15)] was run on March 6, 2018; results were screened to 
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identify eligible COS. Additionally, the COMET database was searched with the keyword pain. Two 
independent reviewers (AC, UK) performed the screening. The methodological quality of a subset of 
14 retrieved COS was assessed by two reviewers (EG, JK) with the Core Outcome Set-STAndards for 
Development (COS-STAD) recommendations (16). One reviewer (AC) extracted data on the targeted 
RMDs and/or intervention(s), on the frequency of pain recommendation, and on the specific pain 
(sub)domains recommended.
Fifty-one COS were retrieved, targeting 37 different RMDs. Seven (14%) focused on a specific 
intervention. None of the 14 COS assessed with COS-STAD met all the minimum quality standards 
(median = 6/11; interquartile range = 5-8). Thirty-seven COS (73%) proposed pain as a core outcome 
domain; in 25 COS it was just labelled pain, in 10 pain intensity was recommended, in 3 pain 
frequency/temporal aspects of pain, and in other 3 pain interference.
Pain intensity measurement
AC reported results of an external group, published elsewhere (17, 18), regarding pain intensity 
measurement for LBP, as an example of issues to consider when deciding about measurement 
instruments for pain domains. This initiative recommended pain intensity as a core outcome 
domain, comprising perspective from clinicians, researchers and patients (10). The three most 
common and frequently recommended measures [i.e. visual analogue scale (VAS), numeric rating 
scale (NRS), and pain severity subscale of the Brief Pain Inventory (BPI-PS)] were assessed in a 
systematic review (18). High-quality evidence was found only for the NRS measurement error, while 
the evidence on all other measurement properties was lower quality (17). In a subsequent Delphi, 
consensus (75%) was found on endorsing the NRS as a core outcome measure for pain intensity in 
LBP trials, with the emphasis (96%) on average intensity over the last week (18).
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Discussion, Conclusion and Next Steps
Although it is clear that chronic pain is felt by patients as a considerable concern and a separate 
aspect of RMDs, a consensus on whether pain is understood as a symptom or a disease cannot be 
easily achieved in the rheumatology field (19). According to the ICD-11 classification, chronic pain is 
considered a separate health condition when meeting specific criteria (20). The pain academic 
community has already acknowledged pain as a symptom but also chronic pain as a complex 
condition with multiple components affecting all aspects of functioning. Hence, the experience of 
chronic pain in RMDs seems to be close to those of chronic pain from other origins, but more 
evidence on patients view is still needed.
The existing number of COS recommendations in RMDs hampers the original idea of harmonizing 
chronic pain assessment by OMERACT. It rather seems to be helpful to consider existing work and 
support future advancements of existing initiatives. An important field of research is identified in the 
investigation of the measurement properties of existent pain scales. Two important questions arise 
from previous discussions about pain measures: 1) the validity of the pain construct; 2) the lacking 
evidence on measurement properties of commonly applied scales. The validity of the pain construct 
has been questioned in other fields, regarding aspects like pain (sub)domains and pain stages (worst, 
average etc.). This may explain why measurement properties lack sufficient evidence base.
During preparatory work and the last two OMERACT meetings, the pain working group has identified 
various subjects for research, three of which may represent the future work of the group:
1) Following the surveys results, beyond pain domains, are there other items (e.g. fatigue, 
sleep) to be measured consistently in RMDs?
2) For pain intensity measurement in RMDs, the NRS may be a simple measure to assess and 
standardize across RMDs, however, more work on other pain (sub)domains is needed to 
better capture the construct multidimensionality.
Page 13 of 19
A
cc
ep
te
d
 A
rt
ic
le
T
h
is
 a
cc
ep
te
d
 a
rt
ic
le
 i
s 
p
ro
te
ct
ed
 b
y
 c
o
p
y
ri
g
h
t.
 A
ll
 r
ig
h
ts
 r
es
er
v
ed
.
 Rheumatology
The Journal of on April 26, 2019 - Published by www.jrheum.orgDownloaded from 
3) The pain experience may (pathophysiologically) range from peripheral to central 
mechanisms, therefore, pain assessment must take this variability into account and address 
these individual patient differences.
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Tables and Figures
Table 1: Characteristics and results of an online survey in patients with RMDs 
Table 2: Importance (Median, 0 not important, 10 of highest importance) of subdomains regarding 
the experience of chronic pain in patients with RMDs and patients from a previous IMMPACT online 
survey
Figure 1: Importance of subdomains regarding the experience of chronic pain in patients with RMDs 
and patients from a previous IMMPAT online survey 
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Table 1:  Characteristics and results of an online survey in patients with RMDs
Total N=72 % n
Whom or whose interests do you represent here?
OMERACT SIG chronic pain 8.33 6
OMERACT other SIG 1.39 1
OMERACT patient research partner 31.94 23
Dragon Claw 13.89 10
UK self support groups 5.56 4
other 38.89 28
Other (please specify) 19,.44 14
How long do have you been engaged in active 
patient participation?
less than 1 year 16.67 12
1.5-3 years 23.61 17
3.5-5 years 9.72 7
5.5-7 years 11.11 8
7.5-9 years 13.89 10
more than 9 years 25.00 18
How long do have you been suffering from RMDs?
less than 1 year 1.39 1
1.5-3 years 11.11 8
3.5-5 years 4.17 3
5.5-7 years 4.17 3
7.5-9 years 9.72 7
more than 9 years 69.44 50
How long do have you been suffering from chronic 
pain?
less than 1 year 8.33 6
1.5-3 years 9.72 7
3.5-5 years 13.89 10
5.5-7 years 2.78 2
7.5-9 years 6.94 5
more than 9 years 58.33 42
As a patient. does chronic pain play a major role in 
your daily life?
yes 84.06 58
no 14.49 10
I do not know 1.45 1
Is chronic pain a separate aspect of RMDs?
yes 22.81 13
no 47.37 27
I do not know 29.82 17
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Table 2: Importance (0 not important, 10 of highest importance) of subdomains regarding the 
experience of chronic pain in patients with RMDs and patients from a previous IMMPACT online 
survey 
Domains of importance OMERACT PRPs IMMPACT
Total number n 72 959
Mean SD Mean SD
falling asleep 7.3 2.79 7.8 2.78
staying asleep 8.0 2.41 8.3 2.45
sex life 6.5 2.75 6.6 3.49
taking care of children 7.2 2.81 7.1 3.36
relations with family 7.7 2.29 7.7 2.75
relations with friends 7.3 2.10 7.2 2.76
Employment 7.4 2.72 7.6 3.25
household activities 7.2 2.19 7.9 2.36
planning activities 7.7 2.22 7.0 2.87
participating in family activities 7.5 2.12 7.7 2.67
participating in recreational and social activities 8.0 1.69 7.7 2.61
physical activities 7.9 1.97 8.4 2.33
hobbies 7.1 2.14 7.1 2.86
Enjoyment of life 8.1 2.10 8.8 2.05
emotional wellbeing 7.4 2.76 8.6 2.27
fatigue. feeling tired 8.3 2.15 8.8 2.01
weakness 6.6 2.70 8.3 2.42
difficulties concentrating 6.6 2.90 8.0 2.62
difficulties remembering things 5.7 3.30 7.6 3.06
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Figure 1: Scores of importance (from 0 to 10) of subdomains regarding the experience of chronic 
pain in patients with RMDs and patients from a previous IMMPACT online survey.
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